m<sup>6</sup>A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 31239444.
- Also identified by DOI 10.1038/s41467-019-10669-0 and PMC identifier 6592937.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Melanoma is one of the most deadly and therapy-resistant cancers. Here we show that N<sup>6</sup>-methyladenosine (m<sup>6</sup>A) mRNA demethylation by fat mass and obesity-associated protein (FTO) increases melanoma growth and decreases response to anti-PD-1 blockade immunotherapy. FTO level is increased in human melanoma and enhances melanoma tumorigenesis in mice. FTO is induced by metabolic starvation stress through the autophagy and NF-κB pathway. Knockdown of FTO increases m<sup>6</sup>A methylation in the critical protumorigenic melanoma cell-intrinsic genes including PD-1 (PDCD1), CXCR4, and SOX10, leading to increased RNA decay through the m<sup>6</sup>A reader YTHDF2. Knockdown of FTO sensitizes melanoma cells to interferon gamma (IFNγ) and sensitizes melanoma to anti-PD-1 treatment in mice, depending on adaptive immunity. Our findings demonstrate a crucial role of FTO as an m<sup>6</sup>A demethylase in promoting melanoma tumorigenesis and anti-PD-1 resistance, and suggest that the combination of FTO inhibition with anti-PD-1 blockade may reduce the resistance to immunotherapy in melanoma.
Medical subject headings
- Adenosine
- Alpha-Ketoglutarate-Dependent Dioxygenase FTO
- Antibodies, Monoclonal
- Melanoma